- ►bloodjournal.org [PDF] PA Cassileth, CB Begg, JM Bennett, M Bozdech, SB … - Blood, 1984 - Am Soc Hematology . Hematology; all rights reserved Copyright 2007 by The American Society of DC 20036. by the
American Society of Hematology, 1900 M St, NW, Suite 200, Washington Blood (print ISSN
0006-4971, online ISSN 1528-0020), is published semimonthly ... For personal use only. ... Cited by 99 - Related articles - All 4 versions
- ►ascopubs.org [PDF] GJ Schiller, SD Nimer, MC Territo, WG Ho, RE … - Journal of Clinical …, 1992 - jco.ascopubs.org Purpose: Despite substantial progress in the treat- ment of acute myeloid leukemia (AML), fewer
than 25% of patients survive free of leukemia for more than 5 years without allogeneic bone marrow
transplantation (BMT). In this study we analyzed the results of one or more cycles of high- ... Cited by 59 - Related articles - All 6 versions
W Hiddemann - Annals of Hematology, 1991 - Springer Page 1. Ann Hematol (1991) 62:119-128 Annals of Hematology 9 Springer-Verlag
1991 Original article Cytosine arabinoside in the treatment of acute myeloid leukemia:
The role and place of high-dose regimens W. Hiddemann ... Cited by 44 - Related articles - All 3 versions
WG Peters, LP Colly, R Willemze - Annals of Hematology, 1988 - Springer Cytosine arabinoside (Ara-C), an analogue of the nucleosides cytidine and deoxycytidine that
acts as a potent inhibitor of DNA replication, was first synthesized in 1959 [1]. Since then
Ara-C has be- come one of the most effective drugs for treatment of acute leukemia. When ... Cited by 33 - Related articles - All 3 versions
WG Peters, R Willemze, LP Colly - Eur J Haematol, 1988 - interscience.wiley.com 50 patients (aged 18–58 years) with acute myelogenous leukaemia after a preleukaemic phase
(n = 14), acute myelogenous leukaemia that previously failed to respond to conventional chemotherapy
(n = 9) or relapsed disease (n = 27) were given remission induction therapy consisting of ... Cited by 14 - Related articles - All 3 versions
ME Trigg, DG Poplack - Science, 1982 - sciencemag.org The ability of antiserum against murine L1210 leukemia to remove residual leukemia cells from
murine bone marrow was investigated. Leukemic marrow was treated in vitro with antiserum
and complement and used to hematologically reconstitute mice that had been irradiated ... Cited by 14 - Related articles - All 3 versions
R Zittoun, M Cadiou, C Bayle, S Suciu, G Solbu, M … - Cancer, 1984 - cat.inist.fr Prognostic value of cytologic parameters acute myelogenous leukemia. R ZITTOUN,
M CADIOU, C BAYLE, S SUCIU, G SOLBU, M HAYAT Cancer 53:77, 1526-1532,
Wiley-Liss, 1984. Une fréquence significativement plus élevée ... Cited by 34 - Related articles - All 2 versions
RM Lowenthal, C Menon, DR Challis - Internal Medicine Journal, 1981 - interscience.wiley.com Abstract: Two consecutive patients with acute myeloid leukaemia (AML) developed severe probable
graft-versus-host disease (GVHD) following transfusion of blood products from normal
donors. In one patient the AML had arisen de novo, while in the other it occurred four ... Cited by 10 - Related articles - All 2 versions
JA Belis, EF Lizza, JC Kim, PC Raich - CA A Cancer Journal for … - interscience.wiley.com Infiltration of the prostate by acute granulocytic leukemia can cause diagnostic and therapeutic
difficulties. After stabilization of hematologic findings, the diagnosis can be made safely by needle
biopsy of the prostate. The prostate may be one of the so-called sanctuary areas where ... Cited by 9 - Related articles - All 2 versions
